Genta Incorporated Announces Third Quarter 2007 Financi...( - New Phase 3 trial of Genasense(R)...),Health

- New Phase 3 trial of Genasense(R) in melanoma opens to global accrual

- Clinical trial opened for G4544 treatment of bone disease

- Named-patient/compassionate-use program ships initial supply

- Appeal filed to review FDA decision on Genasense in CLL - Brief high-dose IV infusions of Genasense well-tolerated in new clinical

trial

BERKELEY HEIGHTS, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today reported financial results for the third quarter ended September 30, 2007 and provided an update on the significant progress made in its pipeline of clinical development programs.

"The third quarter was noteworthy for a number of key initiatives," commented Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "For Genasense, we initiated patient accrual into our global Phase 3 trial in melanoma, known as AGENDA. We secured FDA allowance of the G4544 oral gallium IND and initiated its first clinical trial. We completed the filing of our NDA appeal to FDA in CLL. We showed that brief high-dose infusions of Genasense were well-tolerated, potentially offering new treatment options and improved convenience for patients. Finally, we recorded the first revenues for Genasense from the named-patient program. These are major accomplishments in ambitious programs that should significantly enhance shareholder value."

AGENDA: A randomized Phase 3 trial of Genasense in advanced melanoma

During the 3rd quarter, the first patients were randomized and treated on the AGENDA trial. This trial seeks to confirm the effectiveness and safety of the Genasense/chemotherapy combination in patients who had the
'/>"/>